Barr Pharmaceuticals

Survey: Boomers want sex, many less able

Times of the Internet (Free subscription) | 09/24/2008

MONTVALE, N.J., Sept. 24 (UPI) -- Boomer generation women are less prepared than men for the physical changes associated with menopause that can affect sex, a U.S. survey indicates. A survey by Harris Interactive for Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc., says that 65 percent of women who experienced menopause-induced sexual symptoms report they did not anticipate...

Teva, Barr say FTC wants more info on acquisition

Market Watch (Free subscription) | 09/03/2008

SAN FRANCISCO (MarketWatch) -- The Federal Trade Commission requested additional information from Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals Inc. on Teva's proposed acquisiton of Barr, the companies said Wednesday. The request will extend the antitrust waiting period on the deal by 30 days after the information is supplied. Teva and Barr expect to close the deal in late 2008. In...

• Teva and Barr Receive FTC Request for Additional Information - PR News Wire
• Teva and Barr Receive FTC Request for Additional Information - Business Wire

Barr Cleared to Sell Generic of J&J's Alzheimer's Drug

Law Blog - WSJ.com (Free subscription) | 08/29/2008

Barr Pharmaceuticals said a federal court has invalidated a patent, clearing the way for the generic-drug maker to sell its version of Johnson & Johnson's Razadyne Alzheimer's drug.

Merger Watch: Barr Pharmaceuticals - Teva Pharmaceutical

Seeking Alpha (Free subscription) | 08/22/2008

The M & A Researcher submits: First, this August 14 Financial Times article will be referenced as it essentially echoes this publication's original assessment of the Barr Pharmaceuticals (BRL) - Teva Pharmaceutical (TEVA) transaction upon announcement last month. Of particular interest in this piece are the following passages from an third-part analytical report: An analyst report by Sanford C. Bernstein...

/C O R R E C T I O N -- Barr Pharmaceuticals, Inc. (NYSE: BRL)/

The Earth Times Online Newspaper (Free subscription) | 08/21/2008

In the news release, Barr Pharmaceuticals, Inc. (NYSE: BRL) Announces Barr Announces Approval of Generic Aredia(R) Injection, 30mg/mL, 60mg/mL and 90mg/mL Injectable, issued yesterday, Aug. 20, by Barr Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the...

Zacks Bull and Bear of the Day Highlights: Stone Energy, American Axle, Avnet, Barr Pharmaceuticals and Rogers Communications

Business Wire (Free subscription) | 08/20/2008

CHICAGO--(BUSINESS WIRE)--Zacks Equity Research highlights Stone Energy Corp. (NYSE: SGY) as the Bull of the Day and American Axle (NYSE: AXL) as the Bear of the Day. In

Stada climbs on report Teva in talks to buy it

Market Watch (Free subscription) | 08/15/2008

LONDON (MarketWatch) -- Shares of Stada Arzneimittel rose 12%after the Israeli online financial site Globes reported that Teva Pharmaceutical is in talks to buy Germany's third-largest generics maker even before the Barr Pharmaceuticals deal closes. The report cited unnamed sources and said neither company commented. The site noted that Teva's CEO Shlomo Yanay previously said that the company has...

Barr Labs to settle Mirapex and Aggrenox patent challenges

Medical,Health News and Articles (Free subscription) | 08/13/2008

Medical Patent News Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim’s Mirapex product. Separately, [...]

• Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges - The Earth Times Online Newspaper
• Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges - PR News Wire

Duramed parent Barr settles patent dispute

The Business Courier of Cincinnati (Free subscription) | 08/12/2008

The settlement of a dispute between Barr Pharmaceuticals and Boehringer Ingelheim over generic drugs will benefit Barr subsidiary Duramed Pharmaceuticals. (BRL)

Barr to Settle Boehringer Disputes

Law Blog - WSJ.com (Free subscription) | 08/12/2008

Barr Pharmaceuticals agreed to settle two patent disputes with Boehringer over the German firm's medication for Parkinson's disease and for strokes. Barr also announced supply and promotion deals with Boehringer.

Generic sales help Barr to 2Q profit hike

The Business Courier of Cincinnati (Free subscription) | 08/07/2008

Barr Pharmaceuticals Inc., helped by women’s health products from its Duramed subsidiary, boosted revenues and net income in the second quarter. (BRL)

Barr Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

Seeking Alpha (Free subscription) | 08/07/2008

Barr Pharmaceuticals Inc. (BRL) Q2 FY08 Earnings Call Complete Story »

Wall Street News Alert: Wall Street News Alert: Breaking News Alert - GRCO! August 7, 2008

Market Wire - Investment Opinion (Free subscription) | 08/07/2008

WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: Greenbelt Resources Corporation (PINKSHEETS: GRCO), Sunoco, Inc. (NYSE: SUN), Barr Pharmaceuticals, Inc. (NYSE: BRL) and Assured Guaranty Ltd. (NYSE: AGO).

Barr earnings rise to 52 cents a share in quarter

Market Watch (Free subscription) | 08/07/2008

NEW YORK (MarketWatch) -- Barr Pharmaceuticals Inc. said Thursday that second-quarter earnings were $57 million, or 52 cents a share, compared to $45 million, or 41 cents a share in the same period a year ago. Revenue rose to $779 million compared to $634 million. Analysts polled by FactSet, on average, estimated earnings per share of 54 cents on sales of $626 million. Barr affirmed 2008 adjusted...

Barr profit rises to 52 cents a share in quarter

Market Watch (Free subscription) | 08/07/2008

NEW YORK (MarketWatch) -- Barr Pharmaceuticals Inc. said Thursday that second-quarter earnings were $57 million, or 52 cents a share, compared to $45 million, or 41 cents a share in the same period a year ago. Revenue rose to $779 million compared to $634 million. Analysts polled by FactSet, on average, estimated earnings per share of 54 cents on sales of $626 million. Barr affirmed 2008 adjusted...